Skyhawk Therapeutics publie les résultats à douze mois des sous-composantes de la cUHDRS issus de son essai clinique de phase 1/2 de SKY-0515 dans le traitement de la maladie de Huntington

Skyhawk Therapeutics reported 12-month cUHDRS results for SKY-0515 showing favorable average changes versus baseline across functional and motor outcomes (e.g., TFC +0.07 vs -0.87 in propensity-weighted natural history; TMS -2.00 vs +2.21). Clinician/patient CGI-PGI global impressions showed no observed worsening at 12 months in expected-progressors, with 65% of participants and 50% of clinicians reporting improvement. Biomarker effects were dose-dependent with blood mHTT reductions up to 69% and PMS1 mRNA reductions up to 26%, and the drug was described as generally safe and well-tolerated.

Analysis

This is primarily a platform de-risking event, not a revenue event. The important signal is that an oral CNS small molecule is showing both target engagement and a plausibly translated functional read-through; if that holds, it pressures the premium the market assigns to more burdensome delivery modalities in Huntington’s and, by extension, other CNS rare-disease programs. The incremental winner is the entire “oral, brain-penetrant RNA-modulation” thesis: lower CMC friction, easier chronic dosing, and better real-world adherence should improve partnerability and reduce the discount rate versus intrathecal or one-time approaches.

The second-order loser set is any public competitor whose valuation depends on the assumption that HD will remain an ASO-only market. If future randomized data corroborate the functional trend, it could also pull capital away from broader neurodegeneration baskets toward modality winners with a clearer path to repeat dosing and label expansion. That said, the current readout is still vulnerable to endpoint cherry-picking and small-n noise; open-label impressions and biomarker deltas rarely survive contact with placebo-controlled progression data in neurodegeneration.

The real catalyst path is the next 1-3 months: investors will focus on whether the larger phase 2/3 program can replicate the biomarker slope and preserve cUHDRS separation without safety tradeoffs. Over 6-18 months, the question becomes whether this is a one-program story or proof the SKYSTAR platform can produce a repeatable pipeline. The contrarian risk is that the market overpays for “first signal” optionality before blinded efficacy is visible; if the randomized dataset narrows materially, the stock could retrace sharply even if biomarker reduction remains intact.

Key Decisions for Investors

• No immediate outright trade on the headline; treat this as a de-risking alert and wait for blinded phase 2/3 confirmation before assigning durable probability to efficacy.
• If the market bids the public Huntington’s / RNA-modulation peer set on sympathy, use any strength to short the most valuation-stretched clinical-stage names against a long basket of broader biotech risk (XBI) for 1-4 weeks; the read-through is modality-specific, not sector-wide.
• Watch for partnering/M&A optionality into the next 1-3 months: if management uses these data to secure a large-pharma collaboration, that would be the cleaner long catalyst than the stock alone; upside is high, but only if terms imply external validation of the platform.
• Set a falsifier on the upcoming randomized data: any loss of biomarker durability or disappearance of cUHDRS separation versus placebo should be treated as a thesis break, not a dip-buy.